ZRSR2 gene mutations, found in around 3% of MDS patients [36], are more prevalent in MDS subtypes with no ring sideroblasts and CMML and are associated with an increased percentage of bone marrow blasts and an increased rate of transformation into AML. This evidence concerns the gene ZRSR2 and chronic myelomonocytic leukemia.